<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006246</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068178</org_study_id>
    <secondary_id>PBTC-004</secondary_id>
    <nct_id>NCT00006246</nct_id>
  </id_info>
  <brief_title>Busulfan in Treating Children and Adolescents With Refractory CNS Cancer</brief_title>
  <official_title>Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and&#xD;
      adolescents who have refractory CNS cancer and to estimate the maximum tolerated dose of this&#xD;
      treatment regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicities of intrathecally administered&#xD;
           busulfan in children and adolescents with refractory CNS malignancies.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this treatment regimen in these patients.&#xD;
&#xD;
        -  Determine the cerebrospinal fluid and serum pharmacokinetics of this treatment regimen&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this treatment regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive intrathecal busulfan twice a week, at least 3 days apart, for 2 weeks.&#xD;
      Patients with complete or partial response or stable disease may continue therapy once a week&#xD;
      for 2 weeks, once a week every other week for 2 treatments, and then once a month thereafter&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of busulfan until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose limiting toxicities.&#xD;
&#xD;
      Patients are followed every 3 months for the first year, every 6 months for 4 years, and then&#xD;
      annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 18-24 patients will be accrued for this study over 18-38&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities of IT administered busulfan in children and adolescents with refractory CNS malignancies</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of IT administered busulfan</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum and CSF pharmacokinetics of IT administered busulfan</measure>
  </primary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Retinoblastoma</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed CNS malignancy, including any of the following:&#xD;
&#xD;
               -  Primary malignant brain tumor refractory to standard therapy and metastatic to&#xD;
                  the cerebrospinal fluid (CSF) or leptomeningeal subarachnoid space&#xD;
&#xD;
               -  Recurrent or persistent leptomeningeal leukemia, lymphoma, or germ cell tumor&#xD;
                  refractory to conventional therapy&#xD;
&#xD;
                    -  In second or greater relapse&#xD;
&#xD;
                    -  CSF white blood count greater than 5 cells/mm3 with blasts on cytospin OR&#xD;
&#xD;
                    -  Evidence of leptomeningeal tumor by MRI&#xD;
&#xD;
          -  No concurrent bone marrow disease&#xD;
&#xD;
          -  No obstruction or compartmentalization of CSF flow on CSF flow study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  3 to 21&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Lansky 50-100% (under 10 years)&#xD;
&#xD;
          -  Karnofsky 50-100% (10 to 21 years)&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal for age&#xD;
&#xD;
          -  ALT and AST less than 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  No hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
          -  Glomerular filtration rate greater than 70 mL/min&#xD;
&#xD;
          -  No renal disease&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 1 week since prior intrathecal chemotherapy (2 weeks for cytarabine) and&#xD;
             recovered&#xD;
&#xD;
          -  Evidence of subsequent disease progression&#xD;
&#xD;
          -  Concurrent systemic chemotherapy allowed for recurrent disease after first course of&#xD;
             treatment except for the following:&#xD;
&#xD;
               -  Chemotherapy targeted at leptomeningeal disease&#xD;
&#xD;
               -  Other phase I agent&#xD;
&#xD;
               -  Any agent that significantly penetrates the CSF (e.g., high dose methotrexate&#xD;
                  greater than 1 g/m2, thiotepa, high dose cytarabine, fluorouracil, IV&#xD;
                  mercaptopurine, nitrosoureas, or topotecan)&#xD;
&#xD;
               -  Any agent that causes serious unpredictable CNS side effects&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior dexamethasone allowed with decreasing or stable dose at least one week before&#xD;
             study&#xD;
&#xD;
          -  Concurrent dexamethasone or prednisone with chemotherapy regimen allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 1 week since prior focal irradiation to the brain or spine&#xD;
&#xD;
          -  At least 8 weeks since prior craniospinal irradiation&#xD;
&#xD;
          -  No concurrent cranial or craniospinal irradiation&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent intrathecal or systemic therapy for leptomeningeal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sri Gururangan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 1;12(5):1540-6. doi: 10.1158/1078-0432.CCR-05-2094.</citation>
    <PMID>16533779</PMID>
  </results_reference>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 6, 2009</last_update_submitted>
  <last_update_submitted_qc>October 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>James M. Boyett/PBTC Operations and Biostatistics Center Executive Director</name_title>
    <organization>Pediatric Brain Tumor Consortium</organization>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>leptomeningeal metastases</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood malignant germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

